결막염 치료 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the conjunctivitis treatment market size was valued at USD 4.53 billion in 2025 and estimated to grow from USD 4.71 billion in 2026 to reach USD 5.72 billion by 2031, at a CAGR of 3.98% during the forecast period (2026-2031).

This report is Segmented by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, and Viral Conjunctivitis), Formulation Type (Ointment, Eye Drops, and Oral/Parenteral Drugs), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Conjunctivitis Treatment Market Trends and Insights

Rising Prevalence of Viral & Allergic Conjunctivitis

Seasonal adenoviral outbreaks and climate-linked allergen surges continue to lift overall case counts. Adenovirus strains resist standard antibiotics, pushing demand for targeted antivirals. Climate change is extending pollen seasons, and poor urban air quality magnifies allergic episodes. Pediatric digital lifestyles increase inflammation rates, reinforcing the need for combination anti-inflammatory and anti-infective products. Health systems now frame conjunctivitis as a gateway issue that warrants comprehensive ocular-health management.

Growing OTC Availability of Anti-Infective Eye Drops

Regulators in the United States, Europe, and parts of Asia have reclassified several once-prescription antibiotics for OTC sale. Easier access speeds symptom relief, especially where ophthalmologist density is low. Manufacturers reformulate drops to remove harsh preservatives and simplify dosing. Oversight bodies counter antibiotic misuse risks with consumer education and digital decision-support tools.

Rising Antimicrobial Resistance in Ocular Pathogens

Surveillance studies have documented escalating resistance among Staphylococcus and Streptococcus isolates, limiting first-line therapy effectiveness. Hospitals respond with stewardship programs and demand for next-generation agents, but prolonged development cycles weigh on market expansion.

Other drivers and restraints analyzed in the detailed report include:

1. Expedited FDA Approvals for Ophthalmic Formulations
2. Surge in Screen-Time-Induced Dry-Eye Triggering Secondary Infections
3. API Supply-Chain Disruptions for Ophthalmic Antibiotics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Bacterial conjunctivitis held 36.90% of conjunctivitis treatment market share in 2025. The segment commands higher per-patient spending because culture-guided antibiotic selection is still the clinical norm. Yet antimicrobial resistance trends are reducing the lifespan of established molecules, encouraging premium-priced next-generation launches. The conjunctivitis treatment market size for bacterial infections is expected to rise steadily alongside diagnostic innovations that enable targeted therapy. Allergic conjunctivitis, advancing at a 6.90% CAGR, benefits from OTC antihistamine uptake and climate-driven pollen surges. Manufacturers add mast-cell stabilizers and anti-inflammatory actives to single-dose vials that address both acute itch and chronic redness. Viral cases remain sizeable, though growth is tempered by the self-limited nature of most infections; demand centers on lubricants and symptom-control formulations.

A shift toward preservative-free multidose bottles now influences product choice across disease categories. Innovations such as cationic-oil micro-emulsions deliver prolonged corneal residence, reducing instillation frequency. Clinical guidelines increasingly advocate combination therapy for mixed-etiology presentations, further expanding average selling prices. Against this backdrop, companies that pivot to broad-spectrum or dual-mechanism formulations secure wider formularies and stronger brand loyalty within the conjunctivitis treatment market.

Complete Report Scope:

• By Disease Type
  • Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis
• By Formulation Type
  • Ointments
  • Eye Drops
  • Oral/Parenteral Drugs
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led the conjunctivitis treatment market in 2025 with a 32.40% share. Uptake is driven by insurance coverage that defrays branded-drug copays, sophisticated diagnostic labs that pinpoint causative pathogens, and expedited FDA approvals that fast-track novel agents into clinical practice. Generic disruptions, however, expose supply vulnerabilities and occasionally force therapeutic substitutions, stimulating calls for domestic API hubs. Canada's universal coverage supports equitable access, while Mexico's expanding retail pharmacy chains boost OTC category growth.

Asia-Pacific is the fastest-expanding territory, registering a 7.18% CAGR. China's hospital reforms are streamlining ophthalmology workflows, cutting wait times and lifting prescription volumes. India's tele-ophthalmology pilots screen rural residents and direct confirmed cases to district-level centers, increasing treated incidence. Japan's rapidly aging population remains susceptible to dry-eye-linked infections, propelling demand for lubricating antibiotics. South Korea's high digital-content consumption translates into elevated dry-eye episodes that convert to secondary bacterial conjunctivitis, sustaining premium drop sales.

Europe holds a mature share with stable growth. The region's strict antimicrobial- stewardship protocols temper unnecessary antibiotic use, channeling demand toward narrow-spectrum or combination agents only when culture results justify. Individual markets such as Germany and France favor preservative-free formulations given benzalkonium chloride exposure concerns. Southern European countries are seeing climatically driven allergy seasons that lengthen treatment duration. Middle East and Africa remain under-penetrated but notable public-private eye-care partnerships in the Gulf Cooperation Council are improving access to branded formulations. South America presents restrained, though rising, demand driven by urbanization and insurance reforms that extend ophthalmic cover to broader populations.

1. Abbvie
2. Novartis
3. Bausch + Lomb
4. Santen Pharmaceutical
5. Pfizer
6. Sanofi
7. Nicox
8. Alembic Pharma
9. Auven Therapeutics
10. Sun Pharmaceuticals Industries
11. Teva Pharma
12. Cipla
13. Lupin
14. Ocular Therapeutix
15. Akorn
16. Johnson & Johnson
17. IBA Vision Ophthalmics
18. Sirion Therapeutics
19. Roche
20. Zhaoke Ophthalmology

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence Of Viral & Allergic Conjunctivitis
  • 4.2.2 Growing OTC Availability Of Anti-Infective Eye Drops
  • 4.2.3 Expedited FDA Approvals For Ophthalmic Formulations
  • 4.2.4 Surge In Screen-Time Induced Dry-Eye Triggering Secondary Infections
  • 4.2.5 Climate-Change-Driven Allergen Seasons Lengthening
  • 4.2.6 Tele-Ophthalmology Boosting Early Diagnosis In Rural Areas
• 4.3 Market Restraints
  • 4.3.1 Rising Antimicrobial Resistance In Ocular Pathogens
  • 4.3.2 Growing Popularity Of Herbal & Home-Remedy Alternatives
  • 4.3.3 Stringent Preservatives-Related Regulatory Scrutiny
  • 4.3.4 API Supply-Chain Disruptions For Ophthalmic Antibiotics
• 4.4 Porter's Five Forces
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Disease Type
  • 5.1.1 Allergic Conjunctivitis
  • 5.1.2 Bacterial Conjunctivitis
  • 5.1.3 Viral Conjunctivitis
• 5.2 By Formulation Type
  • 5.2.1 Ointments
  • 5.2.2 Eye Drops
  • 5.2.3 Oral/Parenteral Drugs
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 South Korea
    • 5.3.3.5 Australia
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AbbVie Inc
  • 6.3.2 Novartis AG
  • 6.3.3 Bausch + Lomb
  • 6.3.4 Santen Pharmaceutical
  • 6.3.5 Pfizer Inc
  • 6.3.6 Sanofi SA
  • 6.3.7 Nicox SA
  • 6.3.8 Alembic Pharma
  • 6.3.9 Auven Therapeutics
  • 6.3.10 Sun Pharma
  • 6.3.11 Teva Pharma
  • 6.3.12 Cipla
  • 6.3.13 Lupin Ltd
  • 6.3.14 Ocular Therapeutix
  • 6.3.15 Akorn
  • 6.3.16 Johnson & Johnson Vision
  • 6.3.17 IBA Vision Ophthalmics
  • 6.3.18 Sirion Therapeutics
  • 6.3.19 F. Hoffmann-La Roche
  • 6.3.20 Zhaoke Ophthalmology

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment